During the past decade, Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz conducted 71 clinical trials. In the 10-year time frame, 71 clinical trials started and 29 clinical trials were completed, i.e. on average, 40.8% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 25 clinical trials were completed. i.e. 73.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz" #1 sponsor was "Janssen Research & Development, LLC" with 8 trials, followed by "Celgene" with 6 trials sponsored, "Pfizer" with 6 trials sponsored, "Bayer" with 3 trials sponsored and "Alkahest, Inc." with 3 trials sponsored. Other sponsors include 46 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Australian and New Zealand Intensive Care Research Centre" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz" are "Breast Cancer" (3 trials), "Crohn Disease" (3 trials), "Multiple Sclerosis" (3 trials), "Arthritis, Psoriatic" (2 trials) and "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz" in a lesser frequency.

Most popular intervention types in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz" are "Drug" (70 trials), "Biological" (10 trials), "Other" (6 trials), "Combination Product" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Gemcitabine" (5 trials), "Bendamustine" (4 trials), "Capecitabine" (4 trials) and "Cisplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz" are 69 trials for "All" genders, 4 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz". undefined are not yet recruiting, 20 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, 4 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 54 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".

Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz has several departments that took part in Clinical trials: "Josa Andras Oktatokorhaz / Onkoradiologiai Osztaly" - 3 trials